ArticleACS omega2024
Biochemical, Immunohistochemical, Histopathological, and Apoptotic Evaluation of Nickel Oxide Nanoparticle- and Microparticle-Induced Testicular Toxicity in Male Rats.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Resveratrol regulates nickel oxide-induced kidney damage by targeting the PERK/ATF-6/IRE1 and Nrf2/HO1 pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nickel oxide nanoparticles are engineered particles that are now widely used in medicine, agriculture, and industry applications. This study aimed to investigate subchronic testicular toxicity induced by nickel oxide (NiO) and nickel oxide nanoparticles (NiONPs) in rats by comparing oral, intraperitoneal (IP), and intravenous (IV) routes of administration. Forty-two male Wistar rats were used for the study, and seven groups were formed: control group, NiO oral (150 mg/kg), NiO IP (20 mg/kg), NiO IV (1 mg/kg), NiONP oral (150 mg/kg), NiONP IP (20 mg/kg), and NiONP IV (1 mg/kg). At the end of the 21 day treatment, we collected the testicular tissue of rats to measure biomarkers such as oxidative stress, apoptotic, and inflammatory levels to observe histopathological and immunohistochemical changes. NiO and NiONP treatment caused a decrease in antioxidant activities and AChE levels, an increase in MDA, IL-1β, IL-6, and 8-OHdG levels, a decrease in Bcl-2 expression, and an increase in caspase-3, Bax, and p53 expressions in apoptotic markers. In addition to histopathologic changes in the testicular tissue, an increase in expression of the endoplasmic reticulum stress marker GRP78 was also observed. In conclusion, NiONPs (especially NiONP IV) increased testicular toxicity by disrupting the oxidant-antioxidant balance more than NiO microparticles.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.